Characteristics of solid tumor and lymphoma SMNs
| SMN . | Age at HL dx (y) . | Gender . | HL stage . | Chemotherapy . | RT . | Time to SMN (y) . | SMN site . | SMN in RT field . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Solid tumors | |||||||||
| Embryonal carcinoma | 18 | M | IIIIA | ABVE-PC × 4 | Y | 1.6 | Testis | N | Alive |
| Breast cancer | 17 | F | IB | ABVE-PC × 4 + DECAx2 | Y | 13.4 | Breast | Y | Alive |
| Mucoepidermoid carcinoma | 15 | F | IVA | ABVE-PC × 4 | Y | 6.4 | Parotid gland | Y* | Alive |
| Osteosarcoma | 15 | F | IIB | ABVE-PC × 4 | Y | 5.5 | C3 vertebral body | Y | Alive |
| Papillary adenocarcinoma | 9 | M | IIIA | ABVE-PC × 4 | Y | 9.5 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 14 | M | IIB | ABVE-PC × 4 | Y | 9.2 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 3 | M | IIA | ABVE-PC × 4 | Y | 8.1 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 15 | F | IIB | ABVE-PC × 4 | Y | 4.4 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 16 | M | IIA | ABVE-PC x 4 | Y | 7.2 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 17 | F | IIA | ABVE-PC × 4 | Y | 10.2 | Thyroid | Y | Alive |
| Renal cell carcinoma | 15 | M | IIIA | ABVE-PC × 4 | Y | 13.6 | Kidney | N† | Deceased |
| Lymphoma | |||||||||
| B-NHL | 4 | M | IIB | ABVE-PC × 4 | N | 4.2 | Lacrimal gland | N | Alive |
| T-LL | 14 | M | IIIA | ABVE-PC × 4 | Y | 2.1 | Mediastinum | Y | Deceased |
| Mycosis fungoides | 16 | M | IIB | ABVE-PC × 4 | Y | 6.6 | Skin | Unknown | Alive |
| SMN . | Age at HL dx (y) . | Gender . | HL stage . | Chemotherapy . | RT . | Time to SMN (y) . | SMN site . | SMN in RT field . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Solid tumors | |||||||||
| Embryonal carcinoma | 18 | M | IIIIA | ABVE-PC × 4 | Y | 1.6 | Testis | N | Alive |
| Breast cancer | 17 | F | IB | ABVE-PC × 4 + DECAx2 | Y | 13.4 | Breast | Y | Alive |
| Mucoepidermoid carcinoma | 15 | F | IVA | ABVE-PC × 4 | Y | 6.4 | Parotid gland | Y* | Alive |
| Osteosarcoma | 15 | F | IIB | ABVE-PC × 4 | Y | 5.5 | C3 vertebral body | Y | Alive |
| Papillary adenocarcinoma | 9 | M | IIIA | ABVE-PC × 4 | Y | 9.5 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 14 | M | IIB | ABVE-PC × 4 | Y | 9.2 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 3 | M | IIA | ABVE-PC × 4 | Y | 8.1 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 15 | F | IIB | ABVE-PC × 4 | Y | 4.4 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 16 | M | IIA | ABVE-PC x 4 | Y | 7.2 | Thyroid | Y | Alive |
| Papillary adenocarcinoma | 17 | F | IIA | ABVE-PC × 4 | Y | 10.2 | Thyroid | Y | Alive |
| Renal cell carcinoma | 15 | M | IIIA | ABVE-PC × 4 | Y | 13.6 | Kidney | N† | Deceased |
| Lymphoma | |||||||||
| B-NHL | 4 | M | IIB | ABVE-PC × 4 | N | 4.2 | Lacrimal gland | N | Alive |
| T-LL | 14 | M | IIIA | ABVE-PC × 4 | Y | 2.1 | Mediastinum | Y | Deceased |
| Mycosis fungoides | 16 | M | IIB | ABVE-PC × 4 | Y | 6.6 | Skin | Unknown | Alive |